Second-generation antipsychotics for treating schizophrenia

References

Citations

1. Davis JM, et al. (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry, 60(6): 553–564.

2. Goff DC, et al. (2001). Schizophrenia. Medical Clinics of North America, 85(3): 663–689.

3. U.S. Food and Drug Administration (2003). Safety alert—Risperdal (risperidone). MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Available online: http://www.fda.gov/medwatch/SAFETY/2003/risperdal.htm.

4. Ziprasidone (Geodon) for schizophrenia (2001). Medical Letter on Drugs and Therapeutics, 43(1106): 51–52.

5. U.S. Food and Drug Administration (2006). FDA approves new drug for schizophrenia. FDA News P06-208. Available online: http://fda.gov/bbs/topics/NEWS/2006/NEW01534.html.

6. Rosenheck RA (2006). Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry, 163(12): 2080–2089.

Author:	Jeannette Curtis	Last Updated: February 5, 2008
Medical Review:	Kathleen Romito, MD - Family Medicine Lisa S. Weinstock, MD - Psychiatry
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.